KRAS and lung carcinoma: Of these, we found that the number of the well-recognized driver mutation genes KRAS, and NTRK3 were significantly higher in lung cancer patients with COPD than in those without COPD, while the number of EGFR showed an opposite trend, in accordance with the results of He et al.